What is Amnio Technology?
Amnio Technology is a prominent developer and manufacturer specializing in amnion-derived technologies. The company focuses on producing high-quality, chorion-free products engineered to mitigate graft-versus-host autoimmune responses. Their commitment lies in pioneering innovative regenerative therapies to address unmet needs within wound care and orthopedics. The PalinGen brand encompasses their range of amniotic allografts, designed for both ease of use and therapeutic effectiveness. Amnio Technology's products are utilized across hospitals and clinics nationwide, adhering to stringent quality and regulatory manufacturing standards.
How much funding has Amnio Technology raised?
Amnio Technology has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Amnio Technology
PPP
Public-Private Partnership
What's next for Amnio Technology?
The substantial late-stage funding and recent strategic investment signal a pivotal growth phase for Amnio Technology. This capital infusion is expected to accelerate the expansion of their regenerative therapy pipeline, potentially enhancing their market penetration in wound care and orthopedic applications. The company is poised to further solidify its leadership by scaling production and advancing its innovative product portfolio, leveraging this financial momentum to drive future development and commercialization efforts.
See full Amnio Technology company page
